Jim Wang, Ph.D.

Jim Wang, Ph.D., is Adverum’s senior vice president, head of regulatory affairs, responsible for leading regulatory strategies and execution for the company’s product pipeline. Dr. Wang has more than 17 years of global regulatory experience managing full-spectrum drug development, marketing applications, and regulatory approvals for biologics, gene therapy, and device drug combination products. Most recently, he served as vice president, global head of regulatory strategy at PTC Therapeutics, leading the planning and execution of worldwide regulatory activities across all therapeutic areas focusing on rare disease. He also provided oversight to a cross-functional team for the marketing application of the gene therapy product eladocagene exuparvovec. Previously, he worked with Spark Therapeutics, serving as vice president, head of regulatory affairs strategy. At Spark, he led the Agency interaction and BLA/MAA submission and approval for LUXTURNA® , a gene therapy to treat children and adult patients with an inherited form of vision loss. LUXTURNA® was the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene. In prior positions, he was executive director, global regulatory affairs at Shire Pharmaceutical (now Takeda); senior director at Novo Nordisk responsible for global health authority interaction and marketing applications for Saxenda®; and director of CV, diabetes, and obesity at Bristol-Myers Squibb. Earlier, at Sanofi-Aventis, Dr. Wang served as associate director of CV, thrombosis, and CNS, and led the global regulatory efforts for a late-stage gene therapy product targeting peripheral artery disease. He began his career at Pfizer (formerly Wyeth Pharmaceuticals) serving most recently as manager of regulatory CMC. Dr. Wang earned his Ph.D. in chemistry from the University of Illinois at Urbana-Champaign and an MBA from Pennsylvania State University.